The following posters on psoriasis were curated from all the posters presented at the 73rd annual meeting of the American Academy of Dermatology held March 20-24, 2015, in San Francisco, California. These presentations focus on the long-term safety and efficacy of various psoriasis treatments, costs and health care resource utilization, and comorbidities such as obesity and cardiovascular disease, among patients with psoriasis. 

Faculty

Dermatologists Steven Feldman, MD, PhD, professor of dermatology, pathology, and public health sciences at Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, and Alan Menter, MD, chair of dermatology at Baylor University Medical Center, Dallas, Texas, provide their perspectives on 10 posters on psoriasis from the 2015 annual meeting of the American Academy of Dermatology that deal with the safety and efficacy of psoriasis treatments, comorbidities, and costs.

Target audience

The target learning audience is a national audience of dermatologists and other clinicians who treat patients with moderate to severe psoriasis.

Learning objectives

At the conclusion of this activity, participants should be better able to:

• Summarize the latest research developments in the management of moderate to severe psoriasis
• Incorporate evidence-based research into clinical practice

Instructions

You may participate by listening to any—or all—of the poster discussions. Click the ‘Play’ button to hear our faculty perspectives on selected posters. Two questions will appear at the end of each discussion. When ready to claim your CME credit, click on and complete the “Program Evaluation” first (required) and then click on the “Certificate” to receive your certificate.

This activity is supported by an educational donation provided by Amgen.
This activity is supported by independent educational grants from Celgene Corporation and Novartis Pharmaceuticals Corporation.